CorMedix (CRMD) Competitors $11.24 -0.20 (-1.75%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$11.21 -0.03 (-0.28%) As of 08:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRMD vs. MIRM, ADMA, PTGX, AAPG, MTSR, ZLAB, LNTH, AKRO, MLTX, and KYMRShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Mirum Pharmaceuticals (MIRM), ADMA Biologics (ADMA), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Metsera (MTSR), Zai Lab (ZLAB), Lantheus (LNTH), Akero Therapeutics (AKRO), MoonLake Immunotherapeutics (MLTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. CorMedix vs. Its Competitors Mirum Pharmaceuticals ADMA Biologics Protagonist Therapeutics Ascentage Pharma Group International Metsera Zai Lab Lantheus Akero Therapeutics MoonLake Immunotherapeutics Kymera Therapeutics Mirum Pharmaceuticals (NASDAQ:MIRM) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Which has stronger valuation and earnings, MIRM or CRMD? CorMedix has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$429.16M8.69-$87.94M-$1.21-61.37CorMedix$43.47M20.18-$17.93M$0.7514.99 Do analysts recommend MIRM or CRMD? Mirum Pharmaceuticals currently has a consensus target price of $76.50, suggesting a potential upside of 3.02%. CorMedix has a consensus target price of $18.00, suggesting a potential upside of 60.14%. Given CorMedix's higher probable upside, analysts clearly believe CorMedix is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Is MIRM or CRMD more profitable? CorMedix has a net margin of 42.11% compared to Mirum Pharmaceuticals' net margin of -13.65%. CorMedix's return on equity of 42.73% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-13.65% -24.76% -8.50% CorMedix 42.11%42.73%34.19% Does the media prefer MIRM or CRMD? In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than CorMedix. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 11 mentions for CorMedix. CorMedix's average media sentiment score of 1.20 beat Mirum Pharmaceuticals' score of 0.83 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of MIRM or CRMD? 34.2% of CorMedix shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, MIRM or CRMD? Mirum Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. SummaryCorMedix beats Mirum Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$892.99M$3.15B$5.77B$10.41BDividend YieldN/A2.36%5.68%4.62%P/E Ratio14.9920.7676.0426.42Price / Sales20.18392.57521.33168.33Price / CashN/A45.9137.5661.52Price / Book8.039.8312.876.39Net Income-$17.93M-$52.73M$3.29B$271.13M7 Day Performance-3.85%1.84%0.80%0.93%1 Month Performance-18.14%7.48%4.91%7.52%1 Year Performance44.85%19.92%67.75%30.06% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix3.8842 of 5 stars$11.24-1.7%$18.00+60.1%+49.7%$892.99M$43.47M14.9930MIRMMirum Pharmaceuticals3.4329 of 5 stars$74.19-0.2%$74.44+0.3%+90.5%$3.73B$336.89M-61.31140Analyst ForecastADMAADMA Biologics3.2954 of 5 stars$15.30-5.0%$27.67+80.8%-18.8%$3.65B$474.17M17.79530Positive NewsPTGXProtagonist Therapeutics1.6307 of 5 stars$58.33-0.9%$67.73+16.1%+41.6%$3.63B$434.43M83.33120Insider TradeAAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.60B$134.35M0.00600Gap DownMTSRMetseraN/A$34.21-4.1%$63.50+85.6%N/A$3.59BN/A0.0081Analyst DowngradeZLABZai Lab3.0985 of 5 stars$31.92-2.7%$56.35+76.5%+50.6%$3.57B$427.80M-15.651,869LNTHLantheus4.5336 of 5 stars$51.74-2.3%$89.67+73.3%-52.4%$3.52B$1.52B13.76700Trending NewsAKROAkero Therapeutics3.9879 of 5 stars$42.85-1.4%$81.14+89.4%+69.2%$3.43BN/A-21.4330Positive NewsMLTXMoonLake Immunotherapeutics2.4894 of 5 stars$53.27+1.2%$74.43+39.7%-0.6%$3.42BN/A-19.162Positive NewsKYMRKymera Therapeutics1.8782 of 5 stars$47.28+0.6%$58.76+24.3%+0.2%$3.38B$47.07M-13.63170Analyst Revision Related Companies and Tools Related Companies MIRM Alternatives ADMA Alternatives PTGX Alternatives AAPG Alternatives MTSR Alternatives ZLAB Alternatives LNTH Alternatives AKRO Alternatives MLTX Alternatives KYMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRMD) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts